Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Explore clinical trials studying Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements. Study availability and eligibility vary by location and protocol.

9 public trials 5 recruiting studies

Refine in advanced search Browse all conditions

Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements trial results

Recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

NCT06649812

Conditions: Hemic and Lymphatic Diseases, High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Immune System Diseases, +23 more
Locations: Banner University Medical Center - Tucson Tucson, Arizona, United States

University of Arizona Cancer Center-North Campus Tucson, Arizona, United States

Cedars-Sinai Medical Center Los Angeles, California, United States

Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States

View all 86 locations

View Trial Details

Recruiting

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

NCT06536049

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +22 more
Locations: University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Recruiting

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

NCT07042438

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Recruiting

Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma

NCT05755087

Conditions: Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, +6 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Recruiting

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

NCT03136146

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +29 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

NCT01897012

Conditions: Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +36 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

NCT05821088

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +30 more
Locations: Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Active, Not Recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672

Conditions: ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
Locations: Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States

Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Florida Jacksonville, Florida, United States

Moffitt Cancer Center-International Plaza Tampa, Florida, United States

View all 33 locations

View Trial Details

Active, Not Recruiting

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT05507541

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +36 more
Locations: University of Iowa Iowa City, Iowa, United States

Mayo Clinic Rochester, Minnesota, United States

View Trial Details

Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements trial results

Related conditions